Guangting Zeng
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Guangting Zeng has a total of 19 co-authors. Here are the top co-authors by number of shared publications:
Linlin Wang
Department of Pharmacy, Cancer Center (Xiamen), Fudan University, Xiamen, China
6 shared publicationsXiangting Liu
Reproductive Medicine Center, The First People's Hospital of Chenzhou, Xiangnan University, Chenzhou, China
6 shared publicationsJing Liu
Department of Pharmacy, The First People's Hospital of Chenzhou, Xiangnan University, Chenzhou, China
5 shared publicationsXia Wang
Department of Pharmacy, The First People's Hospital of Chenzhou, Xiangnan University, Chenzhou, China
5 shared publicationsYuchi Zhou
Urology Department, Fourth People’s Hospital of Chenzhou, Chenzhou, China
5 shared publicationsHui Li
Department of Pharmacy, The First People's Hospital of Chenzhou, Xiangnan University, Chenzhou, China
4 shared publications
Latest Publications
- Open Access
- 30 October 2026
- Published by Elsevier in JACC: Advances
- Vol. 5 (12)
Cardiovascular and Cerebrovascular Outcomes Risk Reduction Associated With Semaglutide vs Tirzepatide
- 30 October 2026
- Published by Elsevier in JACC: Advances
- Vol. 5 (12)
Open AccessCardiovascular and Cerebrovascular Outcomes Risk Reduction Associated With Semaglutide vs Tirzepatide
- 1 April 2026
- Published by SAGE Publications in Journal of Oncology Pharmacy Practice
Variability of busulfan area under the concentration-time curve in children with different hematologic disorders
Purpose: Limited data on the effect of hematologic disorders on the busulfan (Bu) pharmacokinetics in children undergoing allogeneic hematopoietic stem cell transplantation (HSCT) is available to date. This study aimed to investigate pharmacokinetic characteristics after the first Bu infusion in children with different hematologic disorders. Methods: A total of 172 Bu concentrations from 43 patients with HSCT and their demographics and characteristics were included to investigate the correlations between different hematologic disorders and Bu concentration or area under the concentration time curve (AUC) using univariate and multivariate regression analysis. Results: Bu concentration and AUC after the first dose were significantly higher in patients with leukemia than in patients with non-malignant hematologic disorders (NMHD) ( P < 0.001). A high variability was observed with 14 (53.8%) of Bu AUC lower than 900 µM × min (3.69 mg × h/L) in patients with NMHD and 15 (88.2%) of Bu AUC higher than 1350 µM × min (5.54 mg × h/L) in patients with leukemia. In univariate analysis, concomitant use of glucocorticoids affected Bu AUC ( P < 0.001). The Bu AUC was significantly correlated with alanine transaminase ( P = 0.004), total bile acids ( P = 0.003) and total bilirubin ( P < 0.001). However, hematologic disorders was the only independent influencing factor of Bu AUC variation, after adjusting for the above variables. Conclusion: Variability in Bu AUC was related to hematologic disorders of children with HSCT, which requires therapeutic drug monitoring and dose adjustment. Different phenotypes of patients should be considered when developing individualized Bu dosing regimen.
- 1 April 2026
- Published by SAGE Publications in Journal of Oncology Pharmacy Practice
Variability of busulfan area under the concentration-time curve in children with different hematologic disorders
Purpose: Limited data on the effect of hematologic disorders on the busulfan (Bu) pharmacokinetics in children undergoing allogeneic hematopoietic stem cell transplantation (HSCT) is available to date. This study aimed to investigate pharmacokinetic characteristics after the first Bu infusion in children with different hematologic disorders. Methods: A total of 172 Bu concentrations from 43 patients with HSCT and their demographics and characteristics were included to investigate the correlations between different hematologic disorders and Bu concentration or area under the concentration time curve (AUC) using univariate and multivariate regression analysis. Results: Bu concentration and AUC after the first dose were significantly higher in patients with leukemia than in patients with non-malignant hematologic disorders (NMHD) ( P < 0.001). A high variability was observed with 14 (53.8%) of Bu AUC lower than 900 µM × min (3.69 mg × h/L) in patients with NMHD and 15 (88.2%) of Bu AUC higher than 1350 µM × min (5.54 mg × h/L) in patients with leukemia. In univariate analysis, concomitant use of glucocorticoids affected Bu AUC ( P < 0.001). The Bu AUC was significantly correlated with alanine transaminase ( P = 0.004), total bile acids ( P = 0.003) and total bilirubin ( P < 0.001). However, hematologic disorders was the only independent influencing factor of Bu AUC variation, after adjusting for the above variables. Conclusion: Variability in Bu AUC was related to hematologic disorders of children with HSCT, which requires therapeutic drug monitoring and dose adjustment. Different phenotypes of patients should be considered when developing individualized Bu dosing regimen.
- 19 March 2026
- Published by Elsevier in The Journal of Pediatrics
- Vol. 294, 115071
Intrauterine SARS-CoV-2 Exposure and Infant Neurodevelopment
- 19 March 2026
- Published by Elsevier in The Journal of Pediatrics
- Vol. 294, 115071
Intrauterine SARS-CoV-2 Exposure and Infant Neurodevelopment
- Open Access
- 23 December 2025
- Published by Elsevier in International Journal of Infectious Diseases
- Vol. 164, 108342
Effectiveness of remdesivir and dexamethasone for patients with confirmed COVID-19: benefit from rational use
- 23 December 2025
- Published by Elsevier in International Journal of Infectious Diseases
- Vol. 164, 108342
Open AccessEffectiveness of remdesivir and dexamethasone for patients with confirmed COVID-19: benefit from rational use
- 8 March 2025
- Published by Springer Nature in Inflammopharmacology
- Vol. 33 (4) , 1861-1862
The association between glucocorticoids and long COVID
- 8 March 2025
- Published by Springer Nature in Inflammopharmacology
- Vol. 33 (4) , 1861-1862
The association between glucocorticoids and long COVID
- 21 December 2024
- Published by Elsevier in Clinical Microbiology and Infection
- Vol. 31 (4) , 664-665
Re: Neurodevelopmental outcomes of infants after in utero exposure to SARS-CoV-2 or mRNA COVID-19 vaccine compared to unexposed infants by Favre et al.
- 21 December 2024
- Published by Elsevier in Clinical Microbiology and Infection
- Vol. 31 (4) , 664-665
Re: Neurodevelopmental outcomes of infants after in utero exposure to SARS-CoV-2 or mRNA COVID-19 vaccine compared to unexposed infants by Favre et al.
- Open Access
- 25 October 2024
- Published by Elsevier in Annals of Intensive Care
- Vol. 14 (1) , 165-2
Corticosteroid treatment in COVID-19 patients receiving extracorporeal membrane oxygenation: benefit from rational use
- 25 October 2024
- Published by Elsevier in Annals of Intensive Care
- Vol. 14 (1) , 165-2
Open AccessCorticosteroid treatment in COVID-19 patients receiving extracorporeal membrane oxygenation: benefit from rational use
- 23 October 2024
- Published by Elsevier in Clinical Microbiology and Infection
- Vol. 31 (3) , 483
Re: ‘Measurement of circulating viral antigens post-SARS-CoV-2 infection in a multicohort study’ by Swank et al.
- 23 October 2024
- Published by Elsevier in Clinical Microbiology and Infection
- Vol. 31 (3) , 483
Re: ‘Measurement of circulating viral antigens post-SARS-CoV-2 infection in a multicohort study’ by Swank et al.
- 2 September 2024
- Published by Springer Nature in Intensive Care Medicine
- Vol. 50 (12) , 2203-2204
Awake prone positioning for COVID-19 patients with acute respiratory failure: unknown appropriate duration
- 2 September 2024
- Published by Springer Nature in Intensive Care Medicine
- Vol. 50 (12) , 2203-2204
Awake prone positioning for COVID-19 patients with acute respiratory failure: unknown appropriate duration
- 26 July 2024
- Published by Elsevier in Clinical Microbiology and Infection
- Vol. 30 (12) , 1616-1617
Re: ‘The efficacy of antivirals, corticosteroids, and monoclonal antibodies as acute COVID-19 treatments in reducing the incidence of long COVID-19’ by Sun et al.
- 26 July 2024
- Published by Elsevier in Clinical Microbiology and Infection
- Vol. 30 (12) , 1616-1617
Re: ‘The efficacy of antivirals, corticosteroids, and monoclonal antibodies as acute COVID-19 treatments in reducing the incidence of long COVID-19’ by Sun et al.